Search the Newsreel

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., August 11, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 26,050 shares of …

Scotts Miracle-Gro (NYSE:SMG) Director Mark Kingdon Sells 831 Shares

What is HC Wainwright's Forecast for MIRM FY2026 Earnings?

Mirum Pharmaceuticals Stock Sinks as Widening Quarterly Loss Offsets Raised Full-Year Sales Guidance

The Scotts Miracle-Gro Company (NYSE:SMG) Given Average Recommendation of "Hold" by Analysts

Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Hennion & Walsh Asset Management Inc. reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 59.9%, selling 56,100 shares and retaining 37,492 shares valued at $4.39 million. This divestment occurred despite Mirum's Q2 revenue beating estimates and management raising its 2026 sales outlook. However, the …

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC)

Two healthcare companies, Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC), have received bullish analyst ratings. TD Cowen maintained a Buy rating for Mirum with a $140.00 price target, and a Strong Buy consensus suggests a 44.8% upside. Encompass Health also received a Buy rating …

Miramar Resources Appoints New Director With Significant Indirect Stake

Scotts Miracle-Gro Company (The (SMG) Stock Forecasts

This article provides a stock forecast for Scotts Miracle-Gro Company (SMG), detailing that its shares fell due to guidance below consensus. Despite this, Morningstar is maintaining its valuation for the company, which is the largest supplier of home lawn and gardening products in the …

MIRM (MIRM) insider Christopher Peetz plans 20,000-share sale after option exercise

Christopher Peetz, an insider at Mirum Pharmaceuticals (MIRM), has filed a Form 144 indicating his intent to sell 20,000 shares of common stock through Morgan Stanley Smith Barney LLC on or after August 10, 2026, following a stock option exercise. The filing also reports …

The Jammu & Kashmir Bank Ltd. Reports Strong Quarterly Financial Turnaround

Mirae Asset Securities Opens August Subscription for Personal Investment Bonds Worth approximately $1.1 Billion

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology

The collaboration will leverage CrystalO's ion channel small-molecule drug discovery platform and Almirall's expertise in skin science to jointly advance an innovative small-molecule program in medical dermatology. CrystalO will conduct candidate discovery, optimization, IND-enabling studies and early clinical development to deliver clinical proof of …

Mirrabooka Investments Discloses Daily On-Market Buy-Back Notification for 5,000 Ordinary Shares

Miramar Resources Discloses Final Director Interest as Terry Gadenne Departs Board

Admiral Group plc Just Missed Revenue By 10%: Here's What Analysts Think Will Happen Next

Is Scotts Miracle Gro (SMG) Undervalued After Reaffirming Guidance And Outlining Growth Targets?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Scotts Miracle-Gro (SMG) stock is back in focus after the CEO outlined progress on the SMG 2.0 plan, reaffirmed full-year guidance, and paired that message …

MIRA Pharmaceuticals Reports Positive Toxicokinetic Data For SKNY-1 In Obesity

(RTTNews) - MIRA Pharmaceuticals Inc. (MIRA), a clinical-stage pharmaceutical company, on Thursday reported positive toxicokinetic data for SKNY-1 to facilitate future studies as a GLP-1 drug with potential for treating obesity. SKNY-1 has shown dose-dependent reductions in body weight alongside lean body mass preservation …

The Bull Case For Mirion Technologies (MIR) Could Change Following New DOE-Focused Perma-Fix Partnership – Learn Why

Mirion Technologies recently partnered with Perma-Fix Environmental Services under the SBA Mentor-Protégé Program to pursue U.S. Department of Energy nuclear cleanup projects. This collaboration leverages Mirion's radiation detection expertise and Perma-Fix's remediation capabilities, potentially enhancing Mirion's long-term federal work. While the partnership adds stability, …

Admiral Group (LSE:ADM) Stock Gets Fair Value Bump As Analysts Rework Targets

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Admiral Group is back in focus after analysts lifted fair value estimates from £34.35 to £36.08 and several banks moved price targets into a …

Mirum Pharmaceuticals (MIRM) Is Down 5.0% After Wider Losses and Volixibat Delay - What's Changed

Mirum Pharmaceuticals reported wider net losses in Q2 2026, reaching US$857.38 million for the first half of the year, despite raising full-year product sales guidance to US$680-US$700 million. The company's stock fell 5.0% due to these losses and a significant delay in the FDA's …

Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold"

Wall Street Zen has upgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "sell" to "hold" despite broader analyst coverage maintaining a "Moderate Buy" rating with a $137.33 price target. This upgrade comes as Mirum Pharmaceuticals reported better-than-expected second-quarter revenues of $176.24 million, a 37.9% year-over-year increase, though …

The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

The Manufacturers Life Insurance Company significantly increased its stake in Mirum Pharmaceuticals (NASDAQ: MIRM) by 63.3% in the first quarter, now holding 55,693 shares valued at $5.15 million. Despite Mirum's Q2 revenue beating estimates at $176.2 million and raised 2026 revenue guidance, the company …

MIRUM PHARMACEUTICALS, INC. : RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $165

Raymond James has increased its target price for MIRUM Pharmaceuticals, Inc. (MIRUM) from $165 to $183. This update indicates a positive outlook from the financial firm regarding the pharmaceutical company's future performance. The article itself is very brief, consisting only of this announcement.

Mirrabooka Investments Ltd Revenue Breakdown – ASX:MIR

Admiral Group plc 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:AMIGY) 2026-08-07

Mirum Pharmaceuticals (MIRM) Stock Sinks As Losses Deepen Despite Higher Guidance

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

MIRA Pharmaceuticals, Inc. announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs, an obesity treatment candidate designed to preserve lean body mass. The study demonstrated rapid oral absorption and dose-dependent systemic exposure, de-risking dose selection and supporting advancement toward …

Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath.

Insmed stock led a biotech rally Thursday, catapulting 34% on solid second-quarter sales for its new lung disease drug, Brinsupri. Continue Reading

MIRUM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $140 FROM $185

H.C. Wainwright has reduced its target price for Mirum Pharmaceuticals Inc. (MIRM.O) from $185 to $140. This announcement was made on August 6, 2026, according to a Reuters report published on Bitget News. The article explicitly states that its content reflects the author's opinion …

Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $138.21, Implies 31% Upside

Mirum Pharmaceuticals, Inc.'s average 12-month price target has been lowered to $138.21 from $145.29, according to 14 analysts. Despite the cut, the new target still suggests a 31% potential upside from the Aug. 5 closing price. The consensus rating remains a "Buy" across all …

Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com

This article announces that Mira Pharmaceuticals Inc. filed a Form 8K on August 6. The content is very brief, mainly serving as a notification about the SEC filing. The company's stock symbol is MIRA, and it showed a 9.11% increase.

Admiral Group PLC (AMIGF) (H1 2026) Earnings Call Highlights: Strong Underwriting Discipline ...

This article first appeared on GuruFocus. Group Profit Before Tax: GBP429 million, down 18% versus H1 2025 but broadly in line with H2 2025. Group Combined Ratio: 78.5%, modestly higher than last year's exceptional 77.7%. Group Loss Ratio: Stable at 57%. Expense Ratio: 21%. …

Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline

Mirum Pharmaceuticals (MIRM) stock dropped 10.4% after the FDA recommended a Phase 3 study for its drug volixibat, delaying its potential NDA submission despite strong second-quarter sales and raised full-year guidance. The regulatory setback for volixibat, intended for cholestatic pruritus due to PSC, has …

FMR LLC (SMG) discloses 4.1M-share position in Scotts Miracle-Gro common stock

FMR LLC has reported a beneficial ownership of 4,096,621.40 shares of The Scotts Miracle-Gro Co. (SMG) common stock, which represents 7.0% of the class. The filing indicates that FMR LLC holds sole voting power over 4,072,438.45 shares and sole dispositive power over all 4,096,621.40 …

RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating

RBC Capital has lowered its price target for Mirum Pharmaceuticals (MIRM) from $148 to $135, while still maintaining an Outperform rating on the stock. This adjustment comes after the company recently reported its Q2 2026 earnings, which showed a wider loss despite increased revenue. …